ADVFN Logo ADVFN

No pudimos encontrar ningún resultado para:
Asegúrate de que la ortografía sea correcta o intenta ampliar tu búsqueda.

Tendencias Ahora

Listas Principales

Parece que no has iniciado sesión.
Haz clic en el botón de abajo para iniciar sesión y ver tu historial reciente.

Regístrate

¿Ya eres miembro? Iniciar sesión

Los Principales Corredores en Línea

Más Corredores en Línea

Datos
Noticias
Herramientas
Mercados
Descubrir

Hot Features

Follow Feed

Conéctese con traders e inversores en nuestra comunidad Follow Feed.

Flujo de Opciones

Explora datos de opciones completos y utiliza filtros avanzados con Options Flow.

Monitor

Organiza y monitorea tu lista de seguimiento de acciones y activos con Monitor.
Iniciar Sesión Premium IconPremium Help Menu
S&P 500
5,286.21
-0.39%
Dow Jones
39,152.82
-1.31%
US Dollar vs MXN
16.703
0.23%
Brent Oil
80.975
-0.68%
Bitcoin
67,849.06
-1.81%
Registration Strip Icon for discussion Regístrate para interactuar en nuestros foros activos para discutir con inversores de ideas afines.
Regístrate
  1. Inicio
  2. Invertir
  3. Acciones
  4. Estados Unidos
  5. NASDAQ
  6. Neoleukin Therapeutics Inc (NLTX)

  7. Neoleukin Therapeutics Inc (NLTX) Noticias

NLTX

Neoleukin Therapeutics (NLTX)

Neoleukin Therapeutics Inc
Fecha:
Ordernar por:
 Showing the most relevant articles for your search:NASDAQ:NLTX
FechaHoraFuenteTítuloSímboloCompañía
10/05/202415:14Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:NLTXNeoleukin Therapeutics Inc
10/05/202406:31Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:NLTXNeoleukin Therapeutics Inc
26/04/202413:34Edgar (US Regulatory)Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) materialNASDAQ:NLTXNeoleukin Therapeutics Inc
26/04/202413:33Edgar (US Regulatory)Form ARS - Annual Report to Security HoldersNASDAQ:NLTXNeoleukin Therapeutics Inc
26/04/202413:33Edgar (US Regulatory)Form DEF 14A - Other definitive proxy statementsNASDAQ:NLTXNeoleukin Therapeutics Inc
18/03/202415:04Edgar (US Regulatory)Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]NASDAQ:NLTXNeoleukin Therapeutics Inc
14/03/202419:54Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:NLTXNeoleukin Therapeutics Inc
07/03/202415:29Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:NLTXNeoleukin Therapeutics Inc
20/02/202415:16Edgar (US Regulatory)Form S-8 - Securities to be offered to employees in employee benefit plansNASDAQ:NLTXNeoleukin Therapeutics Inc
14/02/202417:05Edgar (US Regulatory)Form SC 13G - Statement of acquisition of beneficial ownership by individualsNASDAQ:NLTXNeoleukin Therapeutics Inc
14/02/202415:26Edgar (US Regulatory)Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]NASDAQ:NLTXNeoleukin Therapeutics Inc
18/01/202417:45Edgar (US Regulatory)Form 3 - Initial statement of beneficial ownership of securitiesNASDAQ:NLTXNeoleukin Therapeutics Inc
21/12/202315:05Edgar (US Regulatory)Form SC 13D - General statement of acquisition of beneficial ownershipNASDAQ:NLTXNeoleukin Therapeutics Inc
14/12/202318:00GlobeNewswire Inc.Neoleukin Therapeutics Announces 1-for-4 Reverse Stock SplitNASDAQ:NLTXNeoleukin Therapeutics Inc
06/12/202315:24Edgar (US Regulatory)Form 425 - Prospectuses and communications, business combinationsNASDAQ:NLTXNeoleukin Therapeutics Inc
13/11/202323:15Edgar (US Regulatory)Form EFFECT - Notice of EffectivenessNASDAQ:NLTXNeoleukin Therapeutics Inc
08/11/202313:34Edgar (US Regulatory)Form S-4/A - Registration of securities, business combinations: [Amend]NASDAQ:NLTXNeoleukin Therapeutics Inc
22/09/202307:00GlobeNewswire Inc.Neoleukin Therapeutics Announces 1-for-5 Reverse Stock SplitNASDAQ:NLTXNeoleukin Therapeutics Inc
18/07/202305:30GlobeNewswire Inc.Neurogene and Neoleukin Announce Definitive Merger AgreementNASDAQ:NLTXNeoleukin Therapeutics Inc
12/06/202315:04Edgar (US Regulatory)Statement of Changes in Beneficial Ownership (4)NASDAQ:NLTXNeoleukin Therapeutics Inc
08/05/202315:19Edgar (US Regulatory)Quarterly Report (10-q)NASDAQ:NLTXNeoleukin Therapeutics Inc
27/04/202313:01Edgar (US Regulatory)Annual Report to Security Holders (ars)NASDAQ:NLTXNeoleukin Therapeutics Inc
27/04/202311:48Edgar (US Regulatory)Additional Proxy Soliciting Materials (definitive) (defa14a)NASDAQ:NLTXNeoleukin Therapeutics Inc
27/04/202311:44Edgar (US Regulatory)Proxy Statement (definitive) (def 14a)NASDAQ:NLTXNeoleukin Therapeutics Inc
14/04/202315:52Edgar (US Regulatory)Proxy Statement - Notice of Shareholders Meeting (preliminary) (pre 14a)NASDAQ:NLTXNeoleukin Therapeutics Inc
21/03/202305:02Edgar (US Regulatory)Securities Registration: Employee Benefit Plan (s-8)NASDAQ:NLTXNeoleukin Therapeutics Inc
10/03/202307:20Edgar (US Regulatory)Current Report Filing (8-k)NASDAQ:NLTXNeoleukin Therapeutics Inc
08/03/202316:00GlobeNewswire Inc.Neoleukin Therapeutics Provides Strategic Update and Announces Restructuring and Leadership TransitionNASDAQ:NLTXNeoleukin Therapeutics Inc
14/02/202315:40Edgar (US Regulatory)Amended Statement of Ownership (sc 13g/a)NASDAQ:NLTXNeoleukin Therapeutics Inc
03/02/202310:56Edgar (US Regulatory)Statement of Ownership (sc 13g)NASDAQ:NLTXNeoleukin Therapeutics Inc
 Showing the most relevant articles for your search:NASDAQ:NLTX

Su Consulta Reciente

USOTC
AVCVF
Monitor Ventures (CE)
BOV
APER3R
ALPER ON
USOTC
ODYY
Odyssey (QB)
COIN
PERPBTC
Perpetual
LATK
LYRBTC
Delayed Upgrade Clock
ADVFN Logo

México
Empresa
Negocios
Popular
Obtener la aplicación

Soporte: (55) 4170 8128 | soporte@advfn.mx

Al acceder a los servicios disponibles de ADVFN usted acepta quedar sujerto a los Términos y Condiciones

© 2024 ADVFN PLC - Todos los derechos reservados